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Abstract
Background: Cilostazol(CLZ) has been used as a vasodilating anti-platelet drug clinically and demonstrated to inhibit
proliferation of smooth muscle cells and effect on endothelial cells. However, the effect of CLZ on re-endothelialization
including bone marrow (BM)-derived endothelial progenitor cell (EPC) contribution is unclear. We have investigated the
hypothesis that CLZ might accelerate re-endothelialization with EPCs.
Methodology/Principal Findings: Balloon carotid denudation was performed in male Sprague-Dawley rats. CLZ group was
given CLZ mixed feed from 2weeks before carotid injury. Control group was fed normal diet. CLZ accelerated re-
endothelialization at 2 weeks after surgery and resulted in a significant reduction of neointima formation 4 weeks after
surgery compared with that in control group. CLZ also increased the number of circulating EPCs throughout the time
course. We examined the contribution of BM-derived EPCs to re-endothelialization by BM transplantation from Tie2/lacZ
mice to nude rats. The number of Tie2-regulated X-gal positive cells on injured arterial luminal surface was increased at 2
weeks after surgery in CLZ group compared with that in control group. In vitro, CLZ enhanced proliferation, adhesion and
migration activity, and differentiation with mRNA upregulation of adhesion molecule integrin avb3, chemokine receptor
CXCR4 and growth factor VEGF assessed by real-time RT-PCR in rat BM-derived cultured EPCs. In addition, CLZ markedly
increased the expression of SDF-1a that is a ligand of CXCR4 receptor in EPCs, in the media following vascular injury.
Conclusions/Significance: CLZ promotes EPC mobilization from BM and EPC recruitment to sites of arterial injury, and
thereby inhibited neointima formation with acceleration of re-endothelialization with EPCs as well as pre-existing
endothelial cells in a rat carotid balloon injury model. CLZ could be not only an anti-platelet agent but also a promising tool
for endothelial regeneration, which is a key event for preventing atherosclerosis or restenosis after vascular intervention.
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Introduction
Re-endothelialization inhibits neointimal thickening, thereby
suppressing development of the substrate for lipid deposition and
macrophage accumulation that is believed to induce the formation
of atherosclerotic lesions and may contribute to restenosis. Drug-
elutingstents(DESs)havesignificantlyreducedthe rateofrestenosis;
however, DESs also appear to delay re-endothelialization [1]. This
delay results in excessive rates of thrombosis, which could increase
the occurrence of acute coronary syndromes. Endothelial cell loss
fromarterialwallresulting frommechanicalremoval(hemodynamic
forces, PTCA, stenting) or cell apoptosis, might induce a cascade of
events giving rise to vascular inflammation, smooth muscle cells
proliferation and activation of thrombosis and lead to neointimal
hyperplasia and vascularremodeling,eventually inducing restenosis,
that is key features of atherosclerosis development, progression and
complication. Thrombosis occurs as a consequence of the exposure
of thrombogenic surfaces, both stent and denuded vascular wall, to
blood stream. Therefore, acceleration of re-endothelialization is a
very useful not only to repair endogenously injured vessels, but also
toreduceneointimalformationandpreventintrastentrestenosisand
atherosclerosis development.
Endogenous re-endothelialization is driven not only by
migration and proliferation of resident endothelial cells (ECs)
adjacent to sites of injury, but also with the activity of endothelial
progenitor cells (EPCs). Studies performed in our laboratory and
others demonstrated that both exogenously infused EPCs and
EPCs derived from bone marrow (BM) which can be mobilized to
circulation by ischemia [2,3], physical training [4], and the
administration of statins [5,6], estrogen [7,8], and a variety of
cytokines [9,10,11], recruited to sites of arterial injury, where they
promote re-endothelialization directly by the differentiation into
mature endothelial cells and also indirectly by stimulating resident
ECs and enhancing above process via EPC-released cytokines.
PLoS ONE | www.plosone.org 1 September 2011 | Volume 6 | Issue 9 | e24646Cilostazol (CLZ) is a selective inhibitor of phosphodiesterase 3
(PDE3), and CLZ increases intracellular cAMP content and
activates protein kinase A (PKA) [12], resulting in antiplatelet
aggregation and peripheral vasodilatation. CLZ has therefore been
used as a vasodilating anti-platelet drug for the treatment of
ischemic symptoms in chronic peripheral arterial obstruction or
intermittent claudication and for preventing recurrence of cerebral
infarction [13,14]. CLZ also inhibits vascular smooth muscle cell
proliferation and has been shown to reduce neointima formation
following arterial injury in animal models [15,16,17]. It has also
been demonstrated that CLZ reduces post-procedural in-stent
restenosis (ISR) after coronary artery stenting in the CREST trial
[18,19] and carotid artery stenting. [20] For the mechanistic insight
of anti-neointimal formation, CLZ was shown to protect ECs from
apoptosis induced by serum deprivation, high d-glucose, and
lipopolysaccharide (LPS) [21,22] via a hepatocyte growth factor
production [23] and a suppression of superoxide production
induced by remnant lipoprotein particles [24]. Moreover, it was
reported that CLZ attenuated the expression of vascular cell
adhesion molecule-1 (VCAM-1) [25] and monocyte chemoattrac-
tant protein-1 (MCP-1) [26] and intercellular adhesion molecule
(ICAM-1) and P-selectin [27], as a result, CLZ prevented monocyte
or neutrophil adhesion to endothelial cells. CLZ has pleiotropic
effects on vascular remodeling following injury as described above,
however, the effect of CLZ on re-endothelialization, specifically,
including EPC contribution has not been investigated. We therefore
tested the hypothesis that CLZ might accelerate re-endothelializa-
tion in a rat carotid balloon injury model, and analyzed the
pathophysiological functions of CLZ in EPC biology.
Results
Cilostazol Accelerates Re-endothelialization in Injured
Artery
To evaluate the effect of CLZ on re-endothelialization, the
carotid endothelial recovery following balloon denudation was
assessed by Evans Blue staining. CLZ treatment accelerated re-
endothelialization in the balloon-injured arterial segments.
(Figure 1A) At 2 weeks, the re-endothelialized area in the CLZ-
treated rats (n=7) was 80.465.8% of the total denuded area. In
contrast, the re-endotheliialized area was limited to 49.664.9% of
the total denuded area in the control group (n=7) (P,0.001). At 4
weeks, re-endothelialized area in both control group and CLZ
group were around 90% of the denuded area (91.663.4% vs.
91.463.7%, NS), suggesting that although re-endothelialization
was almost completed at 4 weeks in both groups CLZ accelerated
re-endothelialization in subacute phase which is critical timing for
preventing neointimal development following arterial injury.
(Figure 1B).
Cilostazol Inhibits Neointima Formation following
Arterial Injury
The effect of CLZ on neointimal thickening was also examined
at 2 and 4 weeks after carotid injury. (Figure 2A) In control rats
(n=13), intimal area/medial area (I/M) ratios increased markedly
at 2 weeks (1.3860.10) and 4 weeks (2.1060.17). In contrast, I/M
ratios of animals treated with CLZ (n=13) were 0.6660.11 at
2weeks and 1.2160.33 at 4weeks (P,0.05 vs. control animals).
(Figure 2B) CLZ exhibited statistically significant reduction of
Figure 1. Cilostazol accelerates reendothelialization in injured carotid artery. (A) Rats were given cilostazol mixed feed (Cilostazol group)
or normal diet (Control group) 2 weeks prior to carotid injury until time of sacrifice. Representative photomacrographs of Evans Blue dye staining of
whole-mount en-face carotid arteries at 2 and 4 weeks after carotid balloon denudation. White area represent injured arterial wall covered with
regenerated endothelium, and blue area represent injured arterial wall without endothelium. (B) Quantification of reendothelialized area was
expressed as mean6SEM. *, P,0.001 and NS vs. Control (n=7 in each group).
doi:10.1371/journal.pone.0024646.g001
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tion compared with controls.
Cilostazol Increases Number of Circulating EPCs
To assess the number of circulating EPCs in peripheral blood,
EPC culture assay was performed by double staining of cultured
EPCs with DiI-acLDL and BS1-lectin. (Figure 3-A and 3-B) The
number of circulating EPCs exhibited significant two-fold increase
in CLZ group compared to control group (239625 vs. 113614/
mm
2, P,0.001, n=8) before surgery, and the significant
difference of 2.3-fold increase between CLZ group and control
group sustained until 2 weeks after surgery (380653 vs. 16367/
mm
2, P,0.001, n=5). At 4 weeks after surgery, the number of
circulating EPCs in both groups decreased to similar level (98616
vs. 70610, NS, n=8). (Figure 3-C) Since the number of EPCs
assessed by EPC culture assay correlates with those assessed by
FACS analysis with markers for Sca-1/Flk-1 in mouse peripheral
blood-derived mononuclear cells [7,8], these findings suggest that
CLZ has an effect of EPC mobilization from BM and CLZ further
boosts the mobilization in subacute phase following vascular
injury.
Characterization of EPCs
EPCs derived from peripheral blood were cultured in EPC
differentiation medium for 4 days and characterized by
immunofluorescent staining. Most of the EPCs expressed both
several leukocyte antigens (CD14, CD45, CD34) and endothelial
antigens (CD31, fetal liver kinase 1 (Flk-1), endothelial nitric
oxide synthase (eNOS), von Willebrand factor (vWF)). (Figure
3-D).
Cilostazol Enhances BM-derived EPC Contribution to Re-
endothelialization
To assess the contribution of BM–derived EPCs to accelerated
re-endothelialization, BM from Tie2/lacZ mice was transplanted
to nude rats, and carotid arteries were harvested from Tie2/LacZ
BM transplanted nude rats 2 weeks after balloon injury. In this
model, BM-derived EPCs originated from donor transgenic mouse
are detected by b-galactosidase expression by LacZ gene which is
regulated by endothelial specific Tie2 promotor. The b-galacto-
sidase expression was identified by X-gal chemical staining or by
immunochemical staining in tissue samples. The number of X-gal-
positive cells on luminal surface was significantly greater in CLZ
group (n=5) cells/mm
2 than that in control group (n=5) (4864
vs. 3162 cells/mm
2, P,0.01). (Figure 4A and 4B) In addition,
BM–derived Tie2/LacZ-positive EPCs were further identified by
double-fluorescence immunostaining for b-galactosidase and the
endothelium-specific marker isolectin B4 with cross sections at 2
weeks after carotid injury. In cross sections of carotid arteries from
control group, only a few b-gal-positive and isolectin B4 double-
positive cells were observed on the luminal surface. In contrast,
numerous double-positive cells were observed on the re-endothe-
lialized luminal surface in carotid arteries from CLZ-treated
animals. (Figure 4C) These findings thus suggest that accelerated
re-endothelialization achieved with CLZ involves enhanced EPC
recruitment to the regenerated neoendothelium.
Cilostazol Increases EPC Functions In Vitro
To explore active mechanism of CLZ on rat EPCs, we
performed a series of in vitro studies. The proliferation activity
of EPCs pre-incubated with CLZ was significantly increased
Figure 2. Cilostazol reduces neointima formation in injured carotid artery. (A) Rats were fed with Cilostazol containing diet (Cilostazol
group) or normal diet (control group) from 2 weeks prior to carotid injury until time of sacrifice. Representative photomicrographs of H.E. stained
histological cross sections in Cilostazol group (n=5) vs. Control group (n=6) at 2 and 4weeks after carotid injury. Black arrows indicate internal elastic
lamina. (B) Intima/Media ratio was expressed as mean6SEM. *, P,0.05 and **P,0.01 vs. control.
doi:10.1371/journal.pone.0024646.g002
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manner. (Optical density at 450 nm wavelength: Vehicle
0.14360.002 vs. 1 mM 0.15260.002, P,0.05; 3 mM 0.1526
0.002, P,0.05; 10 mM 0.15760.001, P,0.01; 30 mM 0.1636
0.001, P,0.001). (Figure 5A).
Next, cultured EPCs were incubated with CLZ at the indicated
concentrations for 3 hours for assessment of adhesion activity. The
adhesion activity of EPCs pre-incubated with CLZ was signif-
icantly increased, and CLZ-induced adhesion activity effect was
enhanced peaking at a dose of 10 mM. (Adhered cell number:
Vehicle 69946108 vs. 1 mM 84186241; 3 mM 101566237;
10 mM 113036176; 30 mM 99546231 cells/well, P,0.001).
(Figure 5B).
The migration activity in response to SDF-1a of EPCs pre-
incubated with CLZ was significantly increased compared with
vehicle-treated EPCs in a dose dependent manner. (Migration index:
Vehicle 1.6860.25 vs. 1 mM2 . 2 3 60.16, NS; 3 mM4 . 2 4 60.46
P,0.05; 10 mM 4.6860.67, P,0.001; 30 mM4 . 4 6 61.00, P,0.001)
However,therewasnopromotionaleffectofCLZonVEGF-induced
EPC migration activity. (Figure 5C) This finding allowed us to focus
on the association of CLZ and SDF-1a/CXCR4 signaling pathway
rather than VEGF signaling pathway in EPC biological functions.
Cilostazol Enhances EPC Differentiation and Homing-
related Gene Expression
To investigate whether CLZ has an impact on EPC
differentiation, the effect of CLZ on mRNA expressions of EC
lineage markers CD31 and vWF was examined by quantitative
real-time RT-PCR at 2 days of growth after 3-hour CLZ
treatment with the indicated concentrations. The mRNA
expressions of CD31 and vWF were significantly upregulated in
cultured EPCs with CLZ at doses of 3, 10, and 30 mM (Figure 6A)
and only 30 mM (Figure 6C), respectively. We next further
confirmed the protein expressions of CD31 and vWF in cultured
EPCs by immunofluorescent staining. Numerous staining positive
cells for CD31 (Figure 6B) and vWF (Figure 6D) were observed at
2 days of growth after 3-hour CLZ (30 mM) treatment, while only
a few cells stained positive for CD31and vWF without CLZ. Thus,
by evaluating the expression of 2 different EC markers, CLZ
directly enhanced EPC differentiation to EC lineage in vitro.
Based on the result of EPC adhesion/proliferation activity
increase by CLZ and migration activity increase in response to
SDF-1a but not VEGF as described above, the mRNA expression
of integrin av and integrin b3 which are representative adhesion
molecules in EPCs, CXCR4 which is a receptor for SDF-1a, and
Figure 3. Representative fluorescent images of rat EPC culture assay. (A) Mononuclear cells isolated from 500 ml of peripheral blood were
cultured in EPC differentiation medium for 4days, and stained with acLDL/DiI (red), FITC-conjugated BS-1 lectin (green) and DAPI (blue). (B) Cilostazol
increases number of circulating EPCs. Rats were fed with Cilostazol containing diet (Cilostazol group) or normal diet (Control group) from 2 weeks
prior to carotid injury until time of sacrifice. Representative microphotographs of triple staining with DiI-acLDL and FITC conjugated BS-1 lectin and
DAPI of circulating EPCs cultured for 4days after isolation from peripherial blood just before and at 2 and 4 weeks after balloon injury. (C)
Quantification of circulating EPCs detected by DiI-acLDL/FITC-BS-1 lectin double positive cells in control group (n=8) and the cilostazol-treated
group (n=7) *, P,0.001 vs. Control. (D) Characterization of rat peripheral blood-derived EPCs was performed. After 4 days in culture, cells were
stained by immunofluorescence with antibodies against CD14, CD45, CD34, CD31, Flk-1, eNOS and vWF.
doi:10.1371/journal.pone.0024646.g003
Cilostazol Activates EPC Function
PLoS ONE | www.plosone.org 4 September 2011 | Volume 6 | Issue 9 | e24646VEGF which is a critical growth factor for EPC differentiation,
migration, and proliferation were examined by quantitative real-
time RT-PCR. EPCs were grown for 5 days and were then
incubated with CLZ for 3 hours at the indicated concentrations.
The mRNA expressions of integrin av (Figure 7A) and integrin b3
(Figure 7B) were significantly upregulated by CLZ treatment at a
dose of 10 mM and doses of 10 mM and 30 mM, respectively. CLZ
treatment also upregulated CXCR4 mRNA expression (Figure 7C)
at any concentrations and did VEGF mRNA expression
(Figure 7D) at doses of 10 mM and 30 mM. These findings will
be able to explain the reason of EPC functional activation by CLZ
treatment.
Cilostazol Enhances Medial Expression of SDF-1a in
Injured Artery
We then examined the expression of SDF-1a in injured artery
one week after surgery by both quantitative real-time RT-PCR
and immunofluorescent staining. The SDF-1a mRNA expression
was significantly upregulated in the CLZ–treated rats compared
with that in control rats. (Figure 8A) Next, SDF-1a-positive cells
were identified in injured vascular wall by double-fluorescent
immunostaining for SDF-1a and smooth muscle (SM) a-actin with
cross sections. Only a few/SM a-actin double positive cells were
observed in the media in control animals. In contrast, numerous
double-positive cells were observed in the media in the CLZ-
treated animals (Figure 8B). These data suggest that CLZ enhance
the expression of SDF-1a in the injured artery, specifically, in the
medial vascular smooth muscle cells (VSMCs). Also, the
production of SDF-1a from medial VSMCs might contribute to
the recruitment of CXCR4 positive circulating EPCs.
Discussion
In the present study, we have demonstrated novel biological
effects of CLZ on vascular remodeling following arterial injury,
Figure 4. Cilostazol promotes bone marrow-derived EPC recruitment to denuded carotid artery. (A) Nude rats were transplanted with
bone marrow of Tie2/lacZ mice and fed with Cilostazol containing diet (Cilostazol group) or normal diet (Control group) from 2 weeks prior to carotid
injury until time of sacrifice. Carotid arteries were denuded 6 weeks after bone marrow transplantation and harvested 2 weeks after balloon injury.
Representative photomacrographs of luminal surface of X-gal stained injured. (n=5 in each group) (B) Number of X-gal-positive (blue) cells on
luminal surface was counted and averaged. **P,0.01vs. Control. (C) Representative photographs of double immunofluorescence staining for b-
galactosidase (b-gal, red) and isolectin B4 (green) with cross sections at 2weeks after carotid injury. IEL, internal elastic lamina (Arrowheads); I, intima;
L, lumen; and M, media. Arrows indicate b-gal and isolectin B4-double positive cells.
doi:10.1371/journal.pone.0024646.g004
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endothelialization which is a critical response to vascular injury
in terms of inhibiting neointima formation. The major findings of
this study are: 1) CLZ inhibits neointima formation accelerating
re-endothelialization in injured artery, 2) CLZ-inducd accelerated
re-endothelialization is mediated by EPC mobilization from BM
and circulating EPC recruitment to neoendothelium, 3) CLZ
enhances functional properties, adhesion, migration proliferation,
and differentiation upregulating adhesion molecule integrin avb3,
chemokine receptor CXCR4, and growth factor VEGF mRNA in
EPCs, and 4) CLZ markedly increase the expression of SDF-1a,
which is a ligand for its receptor CXCR4, in medial VSMCs after
injury, suggesting that CLZ accelerates re-endothelialization with
enhanced EPC recruitment via a SDF-1a/CXCR4 axis in injured
arteries.
EPCs were classified into two major cell types according to their
time-dependent appearance in culture, so-called early-outgrowth
EPCs and late-outgrowth EPCs. Early-outgrowth EPCs (eoEPCs)
were obtained by culturing isolated mononuclear cells for 4–7 days
and late-outgrowth EPCs (loEPCs) were appeared after 14–21
days in culture demonstrating acetylated LDL uptake and binding
to Ulex lectin with expressions of CD31, CD34 (generally at low
levels),VE-cadherin, Flk-1 and vWF. Unlike mature endothelial
cells, eoEPCs express a monocyte marker CD14 and a pan-
leucocyte marker CD45 [28,29,30,31]. A beneficial effect on
endothelial repair after injury has been shown by eoEPCs in
previous studies [32,33,34], and cultured EPCs we used in this
study were also characterized as eoEPCs.
As demonstrated in previous studies, EPCs quickly recruit to
sites of vascular injury by cytokines and growth factors [35] and
stimulate neighbouring EC migration and proliferation by
angiogenic growth factor production [36] contributing to
endothelial regeneration in injured arteries. In addition, mainte-
nance of normal number and function of circulating EPCs has
Figure 5. EPC functional assays by Cilostazol treatment. (A) Cilostazol increases EPC proliferation activity. Cultured EPCs were treated with
Cilostazol at the indicated concentrations for 3 h and incubated for further 48 h and proliferation activity was examined by colorimetric assay system.
*, P,0.05; **, P,0.01; and ***, P,0.001 vs. Vehicle. (B) Cilostazol increases EPC adhesion activity. Cultured EPCs were treated with Cilostazol at the
indicated concentrations for 3 h and reseeded on a 96-well plate (5610
4cells/well) with Pronectin F and incubated. After one hour in culture,
adherent cells were fixed and stained with DAPI. DAPI positive cells were counted in 6 different wells under fluorescent microscope (100X) and
averaged. *, P,0.001 vs. Vehicle. (C) Cilostazol increases EPC migration activity. Modified Boyden’s chamber assay was performed. Cultured EPCs were
treated with Cilostazol at the indicated concentrations for 3 h. Cells (1610
5cells) were placed in upper chamber and lower chamber was filled with
medium containing SDF-1a (100 ng/ml) or VEGF (50 ng/ml) or no chemoattractant (negative control) and incubated for 16 h. Migrated cells were
counted following H.E. staining and the migration activity was expressed as a migration index calculated by dividing the number of migrated cells in
the presence of SDF-1a or VEGF by the number of migrated cells in the negative controls. *, P,0.05 and **, P,0.01 vs. Vehicle. All experiments were
performed in triplicate and confirmed the reproducibility.
doi:10.1371/journal.pone.0024646.g005
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PLoS ONE | www.plosone.org 6 September 2011 | Volume 6 | Issue 9 | e24646Figure 6. Cilostazol promotes EPC differentiation to endothelial lineage. Cultured EPCs were treated with Cilostazol at the indicated
concentrations for 3 h and cultured for an additional 48 hours in EPC differentiation medium. Differentiation activity was examined by real-time RT-
PCR analyses for CD31 (A) and vWF (C) mRNA expressions as endothelial markers. *P,0.05 and **P,0.01vs. Vehicle. Representative
immunofluorescence photomicrographs for CD31 (B) and vWF (D) in cultured EPCs treated with Cilostazol. Arrows indicate CD31- and vWF-
positive cells. All experiments were performed in triplicate and confirmed the reproducibility.
doi:10.1371/journal.pone.0024646.g006
Figure 7. Cilostazol alters gene expression profile in cultured EPCs. Cultured EPCs were treated with Cilostazol at the indicated
concentrations for 3 h, and total RNA was extracted. The expressions of adhesion molecule integrin av(A)/integrin b3 (B), chemokine receptor CXCR4
(C) and growth factor VEGF (D) were examined by quantitative real-time RT-PCR analysis. *, P,0.05, **, P,0.01 and *** P,0.001 vs. Vehicle. All
experiments were performed in triplicate and confirmed the reproducibility.
doi:10.1371/journal.pone.0024646.g007
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repair factor [37,38,39]. Therefore, recent studies have proposed
that increase of circulating EPC number and activation of EPC
function are unique strategies to enhance EPC-mediated re-
endothelialization. The evidence of CLZ-induced EPC mobiliza-
tion and homing to sites of injured artery for re-endothelialization
that we have demonstrated in this study may give rise to a novel
therapeutic strategy for vascular remodeling following vascular
intervention as an EPC mobilizer/activator. Our study has also
indicated that CLZ enhanced EPC functional properties of
adhesion, proliferation, and migration exhibiting the following
possible mechanistic insight in the pathophysiological role of EPCs
in re-endothelialization.
Vitronectin, an extracellular matrix protein, has been shown to
influence cellular migration and differentiation [40,41,42], and
Dufourcq et al. showed that VN expression was upreglated in
injured rat carotid artery [43]. Our in vitro data of integrin avb3
mRNA upregulation by CLZ treatment in EPCs can therefore
explain the enhanced EPC adhesion activity against VN and EPC
recruitment to injured vascular wall. Moreover, since interaction
of integrin avb3 and VN is important for cell differentiation [42],
upregulation of integrin avb3 in EPCs is also helpful for EPC
differentiation to EC lineage following the attachment on de-
endothelialized vascular wall. On the other hand, for EPC
recruitment to injured vascular wall, a certain chemokine
produced from injured artery is also crucial as well as adhesion
molecule. Indeed, previous mouse studies have shown that SDF-
1a protein was expressed in injured carotid arteries with a marked
mobilization of circulating Sca-1
+Lineage
2 progenitor cells
involving EPCs in peripheral blood resulting in cell homing to
sites of re-endothelialization, and neutralization of SDF-1a caused
delayed re-endothelialization in injured arteries [44,45,46,47].
The receptor for chemokine SDF-1a, CXCR4, in EPCs are
essential for the homing [45] and CXCR4-blocked EPCs could
not recruit to injured arteries [33,48] In contrast, overexpression
of CXCR4 by gene transfer improves functional properties of
human EPCs and enhances re-endothelialization in injured artery
[49]. These evidences clearly show that SDF-1a/CXCR4 axis is
critical for EPC recruitment to injured vascular wall, and therefore
upregulation of both CXCR4 in circulating EPCs and SDF-1a in
injured medial VSMCs by CLZ treatment might synergistically
promotes EPC-mediated re-endothelialization and CLZ failed to
promote VEGF-induced migration activity of EPCs (Figure 5C) in
our study. In addition, since SDF-1a is a releasing chemokine,
SDF-1a produced from injured medial VSMCs may remotely
influence BM and contribute to EPC mobilization from BM into
circulation. Indeed, a previous report [48] and our data that
timing of EPC mobilization and recruitment to injured arterial
Figure 8. Cilostazol enhances SDF-1 expression in injured carotid artery. Rats were fed with Cilostazol containing diet (Cilostazol group) or
normal diet (control group) from 2 weeks prior to carotid injury until time of sacrifice, and inured arteries were examined at 7 days after surgery. (A)
The expressions of SDF-1 mRNA were examined by quantitative real-time RT-PCR analysis. *, P,0.001 vs. Control. (B) Representative
photomicrographs of double-immunofluorescent staining for SDF-1a shown in red and SM a-actin shown in green on histological cross sections
in Cilostazol group (n=4) vs. Control group (n=3). Arrows indicate double-positive cells for SDF-1a and SM a-actin.
doi:10.1371/journal.pone.0024646.g008
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and 4) could support the above speculation.
CLZ is a clinically available phosphodiesterase 3 (PDE3)
inhibitor, increasing cellar levels of cAMP, with anti-platelet and
vasodilatatory properties [13] and is approved in the US for
treatment of patient with intermittent claudication symptoms
related to peripheral arterial disease [13,50]. Although distinct
mechanism for the favorable effect of CLZ on angiogenesis has not
been shown, one very recent study in which CLZ is shown to
enhance neovascularization in hippocampus in a mouse model of
transient forebrain ischemia via recruitment of BM-derived EPCs
[51] suggest a significant contribution of CLZ-induced EPC
mobilization/recruitment to angiogenesis in ischemic tissue. For
mechanistic insight, as a previous report demonstrated, CLZ
increases NO production by the phosphorylation of eNOS with
increased cAMP levels and enhances endothelial tube formation in
ECs. [52] Since eNOS phosphorylation in BM, in which
endothelial/vascular niche for stem/progenitor cells including
EPCs is involved, is also crucial for EPC mobilization [4,53],
eNOS phosphorylation could be one of the mechanisms of CLZ-
induced EPC mobilization. Furthermore, CLZ might induce
eNOS phosphorylation in EPCs themselves as well as in ECs
resulting in EPC functional activation as Statins did [54]. CLZ has
also been shown to reduce post-procedural in-stent restenosis after
arterial stenting [18,19,20]. DES has dramatically reduced the rate
of restenosis; however, DESs also appears to delay re-endothelia-
lization [1]. This delay results in late angiographic in-stent
thrombosis leading to such as an acute coronary syndrome. For
instance, Sirolimus, one of the coating materials of DES,
accelerates senescence and inhibit proliferation and differentiation,
migration of EPCs [55,56] and EC dysfunction [57], thereby
delayed re-endothelialization [58]. In terms of avoiding adverse
side effects of DES, CLZ treatment following arterial stenting with
DES could be an useful anti-platelet/coagulation therapy for
preventing in-stent thrombosis rather than the other anti-platelet
agents i.e aspirin, ticlopidine, IIb/IIIa antagonist, and so forth.
In conclusion. the results in the present study provided novel
evidences that CLZ inhibited neointima formation following
arterial injury accelerating endothelial regeneration with enhance-
ment of BM-derived EPC mobilization, EPC recruitment to sites
of injured vessel wall, and EPC function. CLZ could be a
promising agent for not only just anti-platelet medicine but also a
tool for vascular regenerative medicine.
Materials and Methods
All procedures and animal care were approved by the
Wakayama medical university Institutional Animal Care and
Use Committee (Approval Number: 351) and the Ethical
Committee in Institute of Biomedical Research and Innovation
(IBRI)/RIKEN Center for Developmental Biology (Approval
Number: AH21-02), and complied with the Japanese Physiological
Society Guidelines for the Care and Use of Laboratory Animal-
s.Cilostazol{6-[4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihy-
dro-2-(1H)-quinolinone} (CLZ) were gifted from Otsuka Pharma-
ceutical (Tokushima, Japan). The Male Sprague-Dawley (SD) rats
(16 to 19 weeks old, 350 to 450 g) were divided into two groups.
One group was fed a standard rat diet (control group), and the
other group was given a 0.2% CLZ mixed diet (CLZ group)
resulting in approximately 60,80 mg/kg/day of CLZ intake.
Previous study showed 50 mg/kg/per day of CLZ intake for 14
days in rat was1.4360.90 mmol/L of plasma concentration
[59],therefore, plasma CLZ level in this study could be equivalent
to the dose in human cases [60]. CLZ containing special diet was
given 2 weeks before and 2 or 4weeks after carotid injury until they
were euthanized. The rats were anesthetized and underwent
carotid balloon denudation as described previously [61]. The
carotid arteries were examined histologically and blood samples
were collected for circulating EPC count before and 2 or 4 weeks
after balloon injury. Detailed materials and methods are available
in Text S1 and Table S1 and Table S2.
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